Xencor (NASDAQ:XNCR) Reaches New 52-Week Low - Time to Sell?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as $12.69 and last traded at $12.89, with a volume of 723182 shares. The stock had previously closed at $12.87.

Analyst Ratings Changes

Several brokerages recently issued reports on XNCR. Wells Fargo & Company reduced their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Piper Sandler raised Xencor from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Finally, StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $34.38.

Xencor Stock Down 2.0 %

The stock has a fifty day moving average of $16.51 and a two-hundred day moving average of $20.30. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $930.10 million, a price-to-earnings ratio of -4.13 and a beta of 0.75.

Remove Ads

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. As a group, analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Xencor

A number of large investors have recently modified their holdings of XNCR. Sterling Capital Management LLC lifted its position in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Xencor during the fourth quarter worth $34,000. GAMMA Investing LLC grew its holdings in Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV grew its holdings in Xencor by 63.5% during the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Quarry LP increased its stake in Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 2,108 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.